We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Developed to Catch Pancreatic Cancer Early

By LabMedica International staff writers
Posted on 08 Sep 2015
Print article
Image: The nCounter Analysis System (Photo courtesy of NanoString Technologies).
Image: The nCounter Analysis System (Photo courtesy of NanoString Technologies).
Pancreatic cancer is the fourth most common cause of cancer-related death in the USA and has a five-year survival rate of only 6%, which is the lowest rate of all types of cancer and this low survival rate is partially attributed to the difficulty in detecting pancreatic cancer at an early stage.

Pancreatic cancer survival rates can be improved by identifying markers in the blood that can pinpoint patients with premalignant pancreatic lesions called intraductal papillary mucinous neoplasms (IPMNs), which can be characterized as either low- or high-risk for the development of pancreatic cancer.

Scientists at the Moffitt Cancer Center (Tampa, FL, USA) and their colleagues developed a fast, cost-effective blood test by studying micro ribonucleic acids (miRNAs), a class of small molecules that regulate key genes involved in the development and progression of cancer. The test can accurately differentiate low-risk IPMNs that can be monitored from high-risk IPMNs that need to be surgically removed. The team measured the abundance of miRNAs in archived preoperative plasma from individuals with pathologically confirmed IPMNs and healthy controls and discovers plasma miRNAs that distinguish between IPMN patients and controls and between “malignant” and “benign” IPMNs.

The scientists used novel nCounter technology (Nanostring Technology, Seattle, WA, USA) to evaluate 800 miRNAs, and showed that a 30-miRNA signature distinguished 42 IPMN cases from 24 controls. The nCounter Analysis System utilizes a novel digital color-coded barcode technology that is based on direct multiplexed measurement of gene expression and offers high levels of precision and sensitivity at less than one copy per cell. The technology uses molecular "barcodes" and single molecule imaging to detect and count hundreds of unique transcripts in a single reaction.

The signature contained novel miRNAs and miRNAs previously implicated in pancreatic carcinogenesis that had two- to four-fold higher expression in cases than controls. They also generated a five-miRNA signature that discriminated between 21malignant, high-grade dysplasia and invasive carcinoma, and 21 benign low- and moderate-grade dysplasia IPMNs, and showed that paired plasma and tissue samples from patients with IPMNs can have distinct miRNA expression profiles.

Jennifer Permuth-Wey, PhD, the first author of the study, said, “IPMNs are established precursor lesions to pancreatic cancer that account for approximately half of all asymptomatic pancreatic cysts incidentally detected by computerized tomography (CT) scans or magnetic resonance imaging (MRI) in the USA each year. The hope is that in the not-so-distant future a miRNA-based blood test can be used in conjunction with imaging features and other factors to aid the medical team in accurately predicting disease severity of IPMNs and other pancreatic cysts at the time of diagnosis or follow-up so that more informed personalized medical management decisions can be made.” The study was published on August 27, 2015, in the journal Cancer Prevention Research.

Related Links:

Moffitt Cancer Center 
Nanostring Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.